Ringing relief? migraine drugs tested for tinnitus in new study

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Non-pulsatile, subjective tinnitus present for at least 6 months * Tinnitus Functional Index (TFI) score greater than 25 at screening, indicating at least mild-to-moderate tinnitus burden * Current or past history of migraine, vestibular migraine, or episodic headache disorder, diagnosed by a physician or meeting ICHD-3 criteria * Clinically appropriate candidate for migraine preventive therapy as determined by the treating clinician * Stable medication regimen for at least 3 months prior to enrollment (no new medications started or stopped within 3 months of screening) * Ability to provide written informed consent * Ability to complete self-report questionnaires in English or with certified interpreter assistance * Willingness to attend three in-person study visits over 24 weeks and complete daily symptom diaries Exclusion Criteria: * Pulsatile tinnitus or objective tinnitus (tinnitus audible to examiner) * Pregnancy, planned pregnancy during the study period, or breastfeeding * Participation in any other interventional tinnitus treatment research protocol during the study period * Currently receiving a CGRP-targeting medication (for participants being considered for the conventional arm) or a conventional migraine preventive medication listed in this protocol (for participants being considered for the CGRP arm) - to avoid within-arm ineligibility at randomization * Known contraindication to all medications within the assigned study arm * History of serious cardiovascular event (myocardial infarction, stroke, or unstable angina) within 6 months of enrollment * Severe hepatic or renal impairment that would contraindicate study medications * Active psychiatric disorder requiring medication adjustment within 3 months of enrollment * Known hypersensitivity or prior serious adverse reaction to a medication within the assigned study arm * Active malignancy or life expectancy less than 12 months * Inability to complete study procedures or follow-up visits in the judgment of the investigator